Gene-Tailored drug dosing aims to protect young transplant patients
NCT ID NCT06529536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using a child's genetic information to guide the dose of the anti-rejection drug tacrolimus can help achieve safer and more effective drug levels after a solid organ transplant. About 45 children aged 1-18 who receive a kidney, liver, or heart transplant will take part. The goal is to reduce side effects from too much or too little medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID ORGAN TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Children's Hospital
RECRUITINGMelbourne, Victoria, 3052, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Video game therapy gets bedridden patients back on their feet
- Could a cancer drug stop a deadly complication in transplant patients?
- Wizard game teaches transplant kids about potions (meds)
- Small study checks COVID-19 vaccine power in young cancer patients
- Supercharged immune cells take on post-transplant viruses
- Could a double-dose flu vaccine protect vulnerable transplant patients better?